Lanini, S;
Easterbrook, PJ;
Zumla, A;
Ippolito, G;
(2016)
Hepatitis C: global epidemiology and strategies for control.
Clinical Microbiology and Infection
, 22
(10)
pp. 833-838.
10.1016/j.cmi.2016.07.035.
Preview |
Text
Zumla 4. Lanini S, Easterbrook, Zumla and Ippolito Final_HCV_global_epi_CLM-16-10295.pdf - Accepted Version Download (199kB) | Preview |
Abstract
It is estimated that globally there are approximately 100 million persons with serological evidence of current or past HCV infection, and that HCV causes about 700 000 deaths each year. The prevalence of infection is the highest in lower and middle income countries, in which a significant number of past infections were caused by iatrogenic transmission and sub-optimal injection safety. In contrast, in developed countries, infections are caused mainly by high-risk exposures and behaviours among specific populations, such as persons who inject drugs. Recently, new direct antiviral activity (DAA) oral drugs with high rates of cure over short duration, which are well tolerated, have made chronic hepatitis C a curable condition. The extraordinary clinical performance of DAAs and recent substantial price reductions and expansion in access in resource-limited settings has provided new impetus for potential control and elimination of hepatitis C as a public health threat. We review the global epidemiology of HCV and the opportunities for preventative and treatment interventions to achieve global control of HCV infection. We also summarize the key elements of the World Health Organization's first-ever global health sector strategy for addressing the viral hepatitis pandemic.
Type: | Article |
---|---|
Title: | Hepatitis C: global epidemiology and strategies for control |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.cmi.2016.07.035 |
Publisher version: | https://doi.org/10.1016/j.cmi.2016.07.035 |
Language: | English |
Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
Keywords: | Science & Technology, Life Sciences & Biomedicine, Infectious Diseases, Microbiology, Control, Epidemiology, Eradication, Global health, Hepatitis C, INJECTING DRUG-USERS, VIRUS-INFECTION, UNITED-STATES, VERTICAL TRANSMISSION, DISEASE BURDEN, HCV INFECTION, SOFOSBUVIR, VELPATASVIR, PREVALENCE, THERAPY |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity |
URI: | https://discovery.ucl.ac.uk/id/eprint/10049260 |
Archive Staff Only
![]() |
View Item |